ENRIQUE REY DÍAZ-RUBIO-rekin lankidetzan egindako argitalpenak (7)

2020

  1. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases

    Alimentary Pharmacology and Therapeutics, Vol. 52, Núm. 2, pp. 276-283

  2. Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2—exploring RAS inhibitors. Authors’ reply

    Alimentary Pharmacology and Therapeutics

  3. Recurrent granulomatous cheilitis associated with Crohn’s disease successfully treated with ustekinumab: case report and literature review

    Therapeutic Advances in Gastroenterology, Vol. 13

2019

  1. Differences in the need for adalimumab dose optimization between Crohn’s disease and ulcerative colitis

    Revista Española de Enfermedades Digestivas, Vol. 111, Núm. 11, pp. 846-851

2018

  1. Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels

    Therapeutic Advances in Gastroenterology, Vol. 11

2014

  1. Need for infliximab dose intensification in Crohn's disease and ulcerative colitis

    World Journal of Gastroenterology, pp. 9170-9177

1996

  1. Topical anesthesia and urease tests [6]

    Gastrointestinal Endoscopy